| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | ACTIVE_NOT_RECRUITING | PHASE2 | 2025-06-03 | 2027-12 | 2027-08 |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | RECRUITING | PHASE1 | 2024-11-04 | 2027-04 | 2026-10 |
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-09-12 | 2026-03 | 2025-06-12 |
| NCT05639751 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-05-02 | 2026-03 | 2026-03 |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | COMPLETED | PHASE1 | 2022-12-27 | 2024-06-26 | 2024-06-26 |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | TERMINATED | PHASE1 | 2022-03-22 | 2024-01-19 | 2024-01-19 |
| NCT05159518 | A Study of PRT2527 in Participants With Advanced Solid Tumors | COMPLETED | PHASE1 | 2022-02-14 | 2023-12-06 | 2023-12-06 |
| NCT04837677 | A Study of PRT1419 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2021-08-11 | 2023-02-06 | 2023-02-06 |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | COMPLETED | PHASE1 | 2020-09-28 | 2022-03-21 | 2022-03-21 |
| NCT04089449 | A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas | COMPLETED | PHASE1 | 2019-11-06 | 2023-03-28 | 2023-03-28 |
| NCT03886831 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies | COMPLETED | PHASE1 | 2019-02-11 | 2022-11-16 | 2022-11-16 |